Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 43.87
(-5.53%)
CNY 43.87
(-5.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 564.38 Million CNY | -12.75% |
| 2022 | 642.77 Million CNY | -12.66% |
| 2021 | 693.97 Million CNY | -17.45% |
| 2020 | 851.73 Million CNY | 26.52% |
| 2019 | 684.51 Million CNY | 48.99% |
| 2018 | 428.6 Million CNY | 29.67% |
| 2017 | 347.42 Million CNY | -42.04% |
| 2016 | 322.4 Million CNY | 22.3% |
| 2015 | 482.81 Million CNY | -13.37% |
| 2014 | 558.78 Million CNY | -6.89% |
| 2013 | 596.88 Million CNY | 18.98% |
| 2012 | 502.44 Million CNY | 29.83% |
| 2011 | 388.1 Million CNY | 4.08% |
| 2010 | 376.57 Million CNY | 15.71% |
| 2009 | 323.45 Million CNY | 42.92% |
| 2008 | 224.17 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 293.86 Million CNY | 67.84% |
| 2024 Q1 | 105.91 Million CNY | -35.47% |
| 2024 Q2 | 139.41 Million CNY | 66.04% |
| 2023 Q4 | 149.93 Million CNY | 1.51% |
| 2023 FY | - CNY | -12.75% |
| 2023 Q1 | 36.65 Million CNY | -87.63% |
| 2023 Q2 | 45.11 Million CNY | 23.09% |
| 2023 Q3 | 147.7 Million CNY | 227.38% |
| 2022 FY | - CNY | -12.66% |
| 2022 Q2 | 52 Million CNY | 46.83% |
| 2022 Q4 | 296.36 Million CNY | 667.22% |
| 2022 Q3 | 38.62 Million CNY | -25.73% |
| 2022 Q1 | 35.42 Million CNY | -61.9% |
| 2021 Q3 | -43.53 Million CNY | -319.24% |
| 2021 Q4 | 92.95 Million CNY | 313.55% |
| 2021 FY | - CNY | -17.45% |
| 2021 Q1 | 472 Million CNY | 68.96% |
| 2021 Q2 | 19.85 Million CNY | -95.79% |
| 2020 Q4 | 279.35 Million CNY | 37.1% |
| 2020 Q1 | 139.72 Million CNY | 9.29% |
| 2020 Q3 | 203.75 Million CNY | 78.99% |
| 2020 FY | - CNY | 26.52% |
| 2020 Q2 | 113.84 Million CNY | -18.52% |
| 2019 Q1 | 64.05 Million CNY | 31.89% |
| 2019 Q3 | 168.81 Million CNY | -21.94% |
| 2019 Q4 | 127.84 Million CNY | -24.27% |
| 2019 FY | - CNY | 48.99% |
| 2019 Q2 | 216.26 Million CNY | 237.6% |
| 2018 Q2 | 93.9 Million CNY | 30.47% |
| 2018 Q4 | 48.57 Million CNY | -69.58% |
| 2018 FY | - CNY | 29.67% |
| 2018 Q1 | 71.97 Million CNY | -8.31% |
| 2018 Q3 | 159.67 Million CNY | 70.05% |
| 2017 Q1 | 7.83 Million CNY | -97.34% |
| 2017 FY | - CNY | -42.04% |
| 2017 Q2 | 144.81 Million CNY | 1749.09% |
| 2017 Q4 | 78.49 Million CNY | -18.62% |
| 2017 Q3 | 96.44 Million CNY | -33.4% |
| 2016 Q3 | 64.85 Million CNY | -74.6% |
| 2016 Q1 | 30.51 Million CNY | -83.07% |
| 2016 Q4 | 293.91 Million CNY | 353.19% |
| 2016 FY | - CNY | 22.3% |
| 2016 Q2 | 255.37 Million CNY | 736.91% |
| 2015 Q4 | 180.21 Million CNY | 239.43% |
| 2015 Q3 | 53.09 Million CNY | -65.62% |
| 2015 Q2 | 154.41 Million CNY | 66.77% |
| 2015 Q1 | 92.59 Million CNY | -57.88% |
| 2015 FY | - CNY | -13.37% |
| 2014 Q2 | 191.47 Million CNY | 173.13% |
| 2014 FY | - CNY | -6.89% |
| 2014 Q4 | 219.81 Million CNY | 90.49% |
| 2014 Q3 | 115.39 Million CNY | -39.74% |
| 2014 Q1 | 70.1 Million CNY | -74.76% |
| 2013 Q2 | 185.94 Million CNY | 199.75% |
| 2013 Q4 | 277.75 Million CNY | 137.42% |
| 2013 FY | - CNY | 18.98% |
| 2013 Q1 | 62.03 Million CNY | -77.25% |
| 2013 Q3 | 116.98 Million CNY | -37.08% |
| 2012 FY | - CNY | 29.83% |
| 2012 Q2 | 88.33 Million CNY | 177.23% |
| 2012 Q3 | 91.86 Million CNY | 4.0% |
| 2012 Q4 | 272.65 Million CNY | 196.79% |
| 2012 Q1 | 31.86 Million CNY | -84.46% |
| 2011 FY | - CNY | 4.08% |
| 2011 Q4 | 205.03 Million CNY | 251.97% |
| 2011 Q3 | 58.25 Million CNY | -50.63% |
| 2011 Q2 | 117.99 Million CNY | 305.94% |
| 2011 Q1 | 29.06 Million CNY | -83.41% |
| 2010 Q3 | 65.95 Million CNY | 0.0% |
| 2010 FY | - CNY | 15.71% |
| 2010 Q4 | 175.19 Million CNY | 165.65% |
| 2009 FY | - CNY | 42.92% |
| 2008 FY | - CNY | 0.0% |